Catalyst
Slingshot members are tracking this event:
Mast Therapeutics (MSTX) Fails to Meet Primary Endpoint in Phase 3 EPIC Trial Evaluating Vepoloxamer in Sickle Cell Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MSTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Primary Endpoint, Phase 3 Epic Trial, Vepoloxamer, Sickle Cell Disease
